Modification of the Early Gene Enhancer-promoter Improves the Oncolytic Potency of Adenovirus 11

作者：Wong Han Hsi; Jiang Guozhong; Gangeswaran Rathi; Wang Pengju; Wang Jiwei; Yuan Ming; Wang Hexiao; Bhakta Vipul; Mueller Heike; Lemoine Nicholas R; Wang Yaohe^*

来源：Molecular Therapy, 2012, 20(2): 306-316.

DOI：10.1038/mt.2011.242

Oncolytic adenoviruses based on serotype 5 (Ad5) have several shortcomings, including the downregulation of its receptor in cancer cells, high prevalence of neutralizing antibodies and hepatotoxicity. Another adenoviral serotype, Ad11, could overcome these obstacles. Here, we show that human cancer cell lines express higher levels of the Ad11 receptor CD46, resulting in much better infectivity than Ad5. Surprisingly, only 36% (9/25) of the cell lines were more sensitive to Ad11- than to Ad5-mediated cytotoxicity. Investigations revealed that it was the transcription of Ad11 E1A, not CD46 expression or virus infectivity, which determined the cell%26apos;s sensitivity to Ad11 killing. Ad11 E1 A mRNA levels have an effect on viral DNA replication, structural protein synthesis and infectious particle production. To test the hypothesis that increased E1A transcription would lead to improved Ad11 replication in Ad5-sensitive (but Ad11-less sensitive) cells, two Ad11 mutants (Ad11-Ads-P and Ad11-Ad5-EP) were constructed where either the E1 A promoter or enhancer-promoter, respectively, was replaced by that of Ad5. Ad11-Ad5-EP demonstrated increased E1 A mRNA levels and replication, together with enhanced oncolytic potency in vitro and in vivo. This effect was found in both the Ad5-sensitive and Ad11-sensitive cancer cells, broadening the range of tumors that could be effectively killed by Ad11-Ad5-EP.

• 出版日期2012-2
• 单位郑州大学